Lewis, Jason S.

Imaging biomarker roadmap for cancer studies

O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology

Medical Imaging Techniques and ApplicationsRadiomics and Machine Learning in Medical Imaging

Cited by 1,091

Biodistribution and Dosimetry of 18 F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies

Pandit-Taskar, N., Zanzonico, P., Staton, K. D., Carrasquillo, J. A., Reidy-Lagunes, D., Lyashchenko, S., Burnazi, E., Zhang, H., Lewis, J. S., Blasberg, R., et al. (2018) · Journal of Nuclear Medicine

Radiopharmaceutical Chemistry and ApplicationsNeuroendocrine Tumor Research Advances

Cited by 136

Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy

Pérez-Medina, C., Abdel-Atti, D., Tang, J., Zhao, Y., Fayad, Z. A., Lewis, J. S., Mulder, W. J. M., & Reiner, T. (2016) · Nature Communications

Nanoparticle-Based Drug DeliveryRadiopharmaceutical Chemistry and Applications

Cited by 128

Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan.

Reidy-Lagunes, D., Pandit-Taskar, N., O'Donoghue, J. A., Krebs, S., Staton, K. D., Lyashchenko, S. K., Lewis, J. S., Raj, N., Gönen, M., Lohrmann, C., et al. (2019) · Clinical Cancer Research

Neuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications

Cited by 112